Kipps T J, Robbins B A, Tefferi A, Meisenholder G, Banks P M, Carson D A
Department of Molecular, Research Institute of Scripps Clinic, La Jolla, California.
Am J Pathol. 1990 Apr;136(4):809-16.
Using monoclonal antibodies (MAb) specific for cross-reactive idiotypes (CRIs) associated with human monoclonal IgM autoantibodies, we examined 57 biopsy specimens that previously had been noted to have immunohistologic features of CD5-positive B-cell small lymphocytic (SL) non-Hodgkin's lymphoma (NHL). Twenty-five lymphoma specimens were noted to be from patients with chronic lymphocytic leukemia (CLL). Eight of thirty-four (24%) immunoglobulin (Ig) kappa light-chain expressing lymphomas reacted with 17.109, a MAb specific for a major CRI encoded by a conserved Ig kappa variable region gene (Vk gene) of the VkIIIb sub-subgroup. All 17.109-reactive tissues and two 17.109-negative specimens were recognized by another MAb specific for VkIIIb framework determinant(s). Seven of all fifty-six (13%) Ig-expressing tumors bound G6, a MAb specific for an autoantibody heavy-chain-associated CRI that is encoded by a conserved antibody heavy chain variable region gene(s) (VHgene) of the VH1 subgroup. All seven G6-positive lymphomas and two G6-negative tumors reacted with Cc1, another MAb specific for a rheumatoid factor heavy-chain-associated CRI. A third autoantibody-heavy-chain-associated CRI, termed Lc1, was expressed by seven (13%) other lymphomas. Finally, a fourth MAb specific for RF heavy-chain-associated CRI, named B6, detected two additional tumors. The expression frequencies of autoantibody-associated CRIs among SL NHL patients without peripheral lymphocytosis did not differ from those noted among patients with CLL but were significantly higher than those observed among patients with NHL of follicular center-cell origin. These data imply that the malignant B cells of patients with either CD5-positive B-cell SL NHL or CLL express a restricted set of Ig V genes that have not substantially diversified from the germline DNA.
我们使用针对与人类单克隆IgM自身抗体相关的交叉反应性独特型(CRIs)的单克隆抗体(MAb),检测了57份活检标本,这些标本之前被发现具有CD5阳性B细胞小淋巴细胞(SL)非霍奇金淋巴瘤(NHL)的免疫组织学特征。25份淋巴瘤标本来自慢性淋巴细胞白血病(CLL)患者。34份表达免疫球蛋白(Ig)κ轻链的淋巴瘤中有8份(24%)与17.109发生反应,17.109是一种针对由VkIIIb亚亚组的保守Igκ可变区基因(Vk基因)编码的主要CRI的单克隆抗体。所有与17.109反应的组织和两份17.109阴性标本都被另一种针对VkIIIb构架决定簇的单克隆抗体识别。56份表达Ig的肿瘤中有7份(13%)与G6结合,G6是一种针对由VH1亚组的保守抗体重链可变区基因(VH基因)编码的自身抗体重链相关CRI的单克隆抗体。所有7份G6阳性淋巴瘤和两份G6阴性肿瘤都与Cc1发生反应,Cc1是另一种针对类风湿因子重链相关CRI的单克隆抗体。另外7份(13%)淋巴瘤表达了第三种自身抗体重链相关CRI,称为Lc1。最后,一种针对RF重链相关CRI的名为B6的第四种单克隆抗体又检测到另外两份肿瘤。外周血淋巴细胞不增多的SL NHL患者中自身抗体相关CRIs的表达频率与CLL患者中观察到的频率没有差异,但显著高于滤泡中心细胞起源的NHL患者中观察到的频率。这些数据表明,CD5阳性B细胞SL NHL患者或CLL患者的恶性B细胞表达一组有限的Ig V基因,这些基因与种系DNA相比没有实质性的多样化。